Ronan Le Moigne

1.2k total citations
27 papers, 367 citations indexed

About

Ronan Le Moigne is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Ronan Le Moigne has authored 27 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 15 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Oncology. Recurrent topics in Ronan Le Moigne's work include Prostate Cancer Treatment and Research (19 papers), Radiopharmaceutical Chemistry and Applications (15 papers) and Cancer Treatment and Pharmacology (10 papers). Ronan Le Moigne is often cited by papers focused on Prostate Cancer Treatment and Research (19 papers), Radiopharmaceutical Chemistry and Applications (15 papers) and Cancer Treatment and Pharmacology (10 papers). Ronan Le Moigne collaborates with scholars based in United States, Canada and France. Ronan Le Moigne's co-authors include Han-Jie Zhou, Mark Rolfe, Mary-Kamala Menon, Antonett Madriaga, Daniel J. Anderson, Bing Yao, Laura K. Shawver, Stevan Djakovic, David J. Wustrow and Steve Wong and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Ronan Le Moigne

26 papers receiving 366 citations

Peers

Countries citing papers authored by Ronan Le Moigne

Since Specialization

Citations

This map shows the geographic impact of Ronan Le Moigne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronan Le Moigne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronan Le Moigne more than expected).

Fields of papers citing papers by Ronan Le Moigne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronan Le Moigne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronan Le Moigne. The network helps show where Ronan Le Moigne may publish in the future.

Co-authorship network of co-authors of Ronan Le Moigne

This figure shows the co-authorship network connecting the top 25 collaborators of Ronan Le Moigne. A scholar is included among the top collaborators of Ronan Le Moigne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronan Le Moigne. Ronan Le Moigne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A PHASE 1B TRIAL OF MASOFANITEN (EPI-7386) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 2025 ·Urologic Oncology Seminars and Original Investigations ·(unknown), Nicholas Iannotti, Russell K. Pachynski, Bradley Curtis Carthon, Kim N., Matthew R. Smith, Fred Saad, Роберто Пили, (unknown), Edmond M. Kwan, Alexander W. Wyatt, (unknown), Brett S. Younginger, Ronan Le Moigne, Alessandra Cesano	0
2	1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects 2024 ·Annals of Oncology ·Christos E. Kyriakopoulos, Gurkamal Chatta, (unknown), Nicholas Iannotti, Alexandra Sokolova, Sébastien J. Hotte, (unknown), Mark C. Markowski, Luke T. Nordquist, Роберто Пили, Fred Saad, Jun Zhang, Karina Villaluna, Brett S. Younginger, Ronan Le Moigne, Alessandra Cesano	2
3	1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results 2023 ·Annals of Oncology ·(unknown), Gurkamal Chatta, Christos E. Kyriakopoulos, Nicholas Iannotti, Sébastien J. Hotte, Mark C. Markowski, Роберто Пили, Jacqueline Vuky, Jun Zhang, Fred Saad, Karina Villaluna, Brett S. Younginger, Ronan Le Moigne, Alessandra Cesano	4
4	Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC). 2023 ·Journal of Clinical Oncology ·(unknown), Gurkamal Chatta, Nicholas Iannotti, Christos E. Kyriakopoulos, (unknown), Ronan Le Moigne, Alessandra Cesano	11
5	Abstract 1209: Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor 2021 ·Cancer Research ·Nan Hyung Hong, Shihua Sun, (unknown), Alessandra Cesano, Elahe A. Mostaghel, Stephen R. Plymate, Han-Jie Zhou, Ronan Le Moigne	1
6	A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer 2021 ·Investigational New Drugs ·Corinne Maurice‐Dror, Ronan Le Moigne, Ulka N. Vaishampayan, Bruce Montgomery, Michael S. Gordon, Nan Hyung Hong, Leah DiMascio, Frank Perabo, Kim N.	23
7	Abstract P192: Comprehensive preclinical characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor 2021 ·Molecular Cancer Therapeutics ·Nan Hyung Hong, Shihua Sun, (unknown), Alessandra Cesano, Elahe A. Mostaghel, Stephen R. Plymate, Bérenger Biannic, Han-Jie Zhou, Ronan Le Moigne	2
8	Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer. 2021 ·Journal of Clinical Oncology ·Ronan Le Moigne, P. Pearson, Veronique Lauriault, Nan Hyung Hong, (unknown), Han-Jie Zhou, Alessandra Cesano	10
9	545P Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer 2020 ·Annals of Oncology ·Ronan Le Moigne, Nan Hyung Hong, P. Pearson, Veronique Lauriault, Carmen A. Bañuelos, Nasrin R. Mawji, (unknown), (unknown), (unknown), Raymond J. Andersen, Marianne D. Sadar, (unknown), Alessandra Cesano	4
10	IND candidate EPI-7386 as an N-terminal domain androgen receptor inhibitor in development for the treatment of prostate cancer. 2020 ·Journal of Clinical Oncology ·Ronan Le Moigne, Carmen A. Bañuelos, Nasrin R. Mawji, Teresa Tam, Jun Wang, (unknown), Raymond J. Andersen, Alessandra Cesano, Marianne D. Sadar, Han-Jie Zhou, (unknown)	8
11	CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity 2019 ·ACS Chemical Biology ·Victoria A. Assimon, (unknown), Jesse D. Vargas, Grace J. Lee, Zhi Wu, (unknown), Bing Yao, Mary-Kamala Menon, (unknown), Kristy C. Perez, Antonett Madriaga, (unknown), Mark Rolfe, Laura K. Shawver, Xian‐Yun Jiao, Ronan Le Moigne, Han-Jie Zhou, Daniel J. Anderson	63
12	Abstract 1292: A new generation of N-terminal domain androgen receptor inhibitors, with improved pharmaceutical properties, in castration-resistant prostate cancer models 2019 ·Cancer Research ·Ronan Le Moigne, Nasrin R. Mawji, Carmen A. Bañuelos, Jun Wang, (unknown), Raymond J. Andersen, Marianne D. Sadar, Han-Jie Zhou, (unknown)	2
13	Abstract B117: Treatment of castrated resistant prostate cancer with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor 2019 ·Molecular Cancer Therapeutics ·Ronan Le Moigne, Carmen A. Bañuelos, Nasrin R. Mawji, Teresa Tam, Jun Wang, (unknown), Raymond J. Andersen, Alessandra Cesano, Marianne D. Sadar, Han-Jie Zhou, (unknown)	5
14	Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models. 2019 ·Journal of Clinical Oncology ·Ronan Le Moigne, Han-Jie Zhou, Nasrin R. Mawji, Carmen A. Bañuelos, Jun Wang, (unknown), (unknown), Raymond J. Andersen, Marianne D. Sadar	1
15	Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor. 2019 ·Journal of Clinical Oncology ·Ronan Le Moigne, Han-Jie Zhou, (unknown), Carmen A. Bañuelos, (unknown), David E. Williams, (unknown), Raymond J. Andersen, Marianne D. Sadar, Frank Perabo, Kim N.	21
16	Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia 2017 ·Neoplasia ·Gabriele Gugliotta, Makoto Sudo, Qi Cao, De‐Chen Lin, Haibo Sun, Sumiko Takao, Ronan Le Moigne, Mark Rolfe, Sigal Gery, Markus Müschen, Michèle Cavo, H. Phillip Koeffler	21
17	Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer 2015 ·Cancer Research ·Daniel J. Anderson, Ronan Le Moigne, Stevan Djakovic, Brajesh Kumar, Julie Rice, Steve Wong, Jinhai Wang, Bing Yao, Eduardo Valle, (unknown), Szerenke Kiss Von Soly, Antonett Madriaga, (unknown), (unknown), Alessandra Cesano, Han-Jie Zhou, David J. Wustrow, Mark Rolfe	2
18	Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083) 2015 ·Journal of Medicinal Chemistry ·Han-Jie Zhou, Jinhai Wang, Bing Yao, Steve Wong, Stevan Djakovic, Brajesh Kumar, Julie Rice, Eduardo Valle, Ferdie Soriano, Mary-Kamala Menon, Antonett Madriaga, Szerenke Kiss Von Soly, (unknown), Francesco Parlati, F. Michael Yakes, Laura K. Shawver, Ronan Le Moigne, Daniel J. Anderson, Mark Rolfe, David J. Wustrow	146
19	Abstract 951: CB-5083 is a novel first in class p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models 2014 ·Cancer Research ·Ronan Le Moigne, Steve Wong, Ferdie Soriano, Eduardo Valle, Daniel J. Anderson, Stevan Djakovic, Mary-Kamala Menon, Bing Yao, Julie Rice, Jinhai Wang, Szerenke Kiss Von Soly, Brajesh Kumar, Marta Chesi, P. Leif Bergsagel, Han-Jie Zhou, David J. Wustrow, Mark Rolfe, F. Michael Yakes	1
20	Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel or gemcitabine results in greater antitumor activity in tumor bearing mice. 2008 ·Cancer Research ·Pascale Lejeune, Marielle Chiron, Ronan Le Moigne, Patricia Vrignaud, Marie-Christine Bissery	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact